Mode
Text Size
Log in / Sign up

AI systems perform comparably to radiologists for detecting clinically significant prostate cancer on mpMRIArtificial intelligence shows promise in detecting prostate cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that AI systems perform comparably to radiologists for csPCa detection on mpMRI but require prospective validation.

This meta-analysis evaluates the performance of artificial intelligence systems, specifically convolutional neural networks and deep learning, compared to experienced radiologists in detecting clinically significant prostate cancer (csPCa) on multiparametric magnetic resonance imaging. The analysis included 2586 patients across various studies.

Key findings indicate that AI achieved a sensitivity of 0.90 (95% CI 0.84-0.94) and a specificity of 0.69 (95% CI 0.45-0.85). Radiologists demonstrated a sensitivity of 0.89 (95% CI 0.82-0.94) and a specificity of 0.60 (95% CI 0.43-0.75). The diagnostic odds ratio for AI was 17.54 (95% CI 9.34-32.94), compared to 12.35 (95% CI 4.96-30.76) for radiologists. The area under the receiver operating curve was 0.88 for AI versus 0.85 for radiologists.

The authors note that the evidence is limited by high heterogeneity and the retrospective nature of all included studies. While AI showed a higher specificity, this difference was not statistically significant due to overlapping confidence intervals. These findings suggest AI could serve as an adjunct tool to improve precision and reduce unnecessary biopsies in clinical practice.

How this fits prior evidence

This meta-analysis extends prior evidence indicating that artificial intelligence improves diagnostic accuracy and treatment planning in prostate cancer management. While the previous finding noted technical limitations hindering widespread use, this study provides specific performance metrics for mpMRI interpretation, showing AI performs comparably to radiologists with a potential edge in specificity.

When doctors look for prostate cancer, they rely heavily on magnetic resonance imaging (MRI). Because accuracy is vital for deciding who needs a biopsy and who does not, researchers looked at how well artificial intelligence (AI) compares to experienced human experts. The study analyzed data from over 2,500 cases to see if computers could help catch the most serious forms of the disease.

The results showed that AI systems were very effective at finding clinically significant prostate cancer. In fact, the AI had a slightly higher specificity score than radiologists, meaning it was potentially better at identifying which areas were healthy. While both humans and machines performed well, the AI's overall diagnostic performance was slightly higher in some measures.

It is important to note that these findings come from older, retrospective data, which means the results are not yet proven in real-time clinical settings. Because the studies involved many different methods, there is still a need for more consistent testing. For now, AI could serve as a helpful tool to help doctors be more precise and reduce unnecessary procedures.

What this means for you:
AI shows high accuracy in detecting prostate cancer on MRI scans, potentially helping doctors avoid unnecessary biopsies.

Common questions

Is AI better than a human radiologist?

AI and radiologists performed very similarly. The AI had a slightly higher specificity score (0.69) compared to radiologists (0.60), but because the data comes from various sources, these results are not yet considered statistically significant.

Can AI help reduce unnecessary biopsies?

Because AI shows high accuracy and a potential edge in specificity, it could serve as an extra tool for doctors. This may help them be more precise and potentially reduce the number of patients who need unnecessary biopsies.

Study Details

Study typeMeta analysis
Sample sizen = 2,586
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
OBJECTIVE: Multiparametric magnetic resonance imaging (mpMRI) detects clinically significant prostate cancer (csPCa, Gleason Grade Group ≥ 2) with high sensitivity but limited specificity and inter-reader variability. Artificial intelligence (AI), particularly convolutional neural networks (CNNs) and deep learning, may improve diagnostic consistency and accuracy. This meta-analysis compares AI systems and experienced radiologists in detecting csPCa using mpMRI. METHODS: We performed a systematic review and meta-analysis of English-language non-RCT studies. PubMed, Embase, and Cochrane databases were searched up to May 2025, yielding 855 studies. Only studies comparing CNN-based or deep-learning AI models to radiologists were included. Pooled sensitivity, specificity, diagnostic odds ratio (DOR), and area under the receiver operating curve (AUC) were calculated using a bivariate random-effects model. RESULTS: Ten studies with 2586 patients were analyzed. AI systems showed pooled sensitivity of 0.90 (95% CI 0.84-0.94) and specificity of 0.69 (95% CI 0.45-0.85). Radiologists had a sensitivity of 0.89 (95% CI 0.82-0.94) and a specificity of 0.60 (95% CI 0.43-0.75). DOR was 17.54 (95% CI 9.34-32.94) for AI and 12.35 (95% CI 4.96-30.76) for radiologists. Summary receiver operating characteristic (SROC) curves indicated similar diagnostic accuracy, with AI slightly outperforming radiologists (AUC 0.88 vs. 0.85). CONCLUSION: AI systems perform comparably to radiologists in detecting csPCa on mpMRI, with a potential edge in specificity, though confidence intervals overlapped. High heterogeneity and the retrospective nature of all included studies limit reliability, necessitating prospective validation. AI could serve as an adjunct in prostate cancer diagnosis, potentially improving precision and reducing unnecessary biopsies with further model refinement. KEY POINTS: Question Interpretation of mpMRI for clinically significant prostate cancer varies among radiologists, affecting diagnostic consistency. Findings Meta-analysis shows AI has comparable sensitivity and potentially superior specificity to radiologists in detecting significant prostate cancer on mpMRI, though confidence intervals overlapped. Clinical relevance AI has the potential to enhance diagnostic accuracy, reduce unnecessary biopsies, and improve consistency in prostate cancer detection, thereby supporting more reliable and standardized imaging assessments across centers.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.